BURON NUTRASCIENCE CORP (BRCNF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for FY2022, filed Aug 1, 2022. Each column of the statement tables below links to the filing it was taken from.
BURON NUTRASCIENCE CORP (BRCNF) reported $137K in revenue for fiscal year 2022, down 33.2% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
BURON NUTRASCIENCE CORP does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
BURON NUTRASCIENCE CORP scores 2.13, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $11.6M against total liabilities of $883K. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BURON NUTRASCIENCE CORP passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
BURON NUTRASCIENCE CORP reported a net loss of $8.2M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
BURON NUTRASCIENCE CORP reported an operating loss of $5.9M against $58K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
BURON NUTRASCIENCE CORP generated $137K in revenue in fiscal year 2022. This represents a decrease of 33.2% from the prior year.
BURON NUTRASCIENCE CORP's EBITDA was -$5.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. The change from the prior year is not meaningful, because that figure was zero or negative.
BURON NUTRASCIENCE CORP reported a net loss of $8.2M in fiscal year 2022. The change from the prior year is not meaningful, because that figure was zero or negative.
BURON NUTRASCIENCE CORP earned -$0.07 per diluted share (EPS) in fiscal year 2022.
Cash & Balance Sheet
BURON NUTRASCIENCE CORP recorded an outflow of $4.8M in free cash flow in fiscal year 2022, representing a cash shortfall after capex. The change from the prior year is not meaningful, because that figure was zero or negative.
BURON NUTRASCIENCE CORP held $5.6M in cash as of fiscal year 2022; no long-term debt figure is on record for that period.
Not reported for fiscal year 2022.
Margins & Returns
BURON NUTRASCIENCE CORP's ROE was -36.3% in fiscal year 2022, measuring profit generated per dollar of shareholder equity. This is down 34.6 percentage points from the prior year.
Not reported for fiscal year 2022.
Not shown for fiscal year 2022: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2022: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
BURON NUTRASCIENCE CORP invested $1.5M in research and development in fiscal year 2022. This represents an increase of 349.0% from the prior year.
BURON NUTRASCIENCE CORP invested $41K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 94.2% from the prior year.
Not reported for fiscal year 2022.
BRCNF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|
| Revenue | $137K-33.2% | $206K+833.3% | $22K |
| R&D Expenses | $1.5M+349.0% | $329K-35.6% | $511K |
| Operating Income | -$5.9Mn/m | -$3.7Mn/m | -$2.6M |
| EBITDA | -$5.8Mn/m | -$3.6Mn/m | -$2.6M |
| Interest Expense | $58K-90.5% | $613K+46.9% | $417K |
| Income Tax | $0n/m | $0n/m | $0 |
| Net Income | -$8.2Mn/m | -$491Kn/m | -$3.3M |
| EPS (Diluted) | -$0.07 | -$0.01n/m | -$0.04 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, SG&A Expenses, EPS (Basic), Diluted Shares (Avg).
BRCNF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|
| Total Assets | $23.5M-21.6% | $30.0M+35.5% | $22.1M |
| Current Assets | $6.1M-47.5% | $11.6M+3.9% | $11.2M |
| Cash & Equivalents | $5.6M-49.5% | $11.1M+4.4% | $10.6M |
| Inventory | $0-100.0% | $105K+12.6% | $94K |
| Accounts Receivable | $161K-40.4% | $269K+14.5% | $235K |
| Goodwill | $1.0M+0.7% | $998K+12.3% | $889K |
| Total Liabilities | $883K-23.5% | $1.2M-80.4% | $5.9M |
| Current Liabilities | $836K-27.3% | $1.2M+2.1% | $1.1M |
| Non-Current Liabilities | $47K+1023.4% | $4K-99.9% | $4.8M |
| Total Equity | $22.6M-21.6% | $28.9M+77.6% | $16.2M |
| Retained Earnings | -$87.5Mn/m | -$78.7Mn/m | -$69.6M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Long-Term Debt.
BRCNF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|
| Operating Cash Flow | -$4.7Mn/m | -$2.4Mn/m | -$2.4M |
| Depreciation & Amortization | $125K+27.5% | $98K+271.3% | $26K |
| Capital Expenditures | $41K-94.2% | $712K+893.2% | $72K |
| Free Cash Flow | -$4.8Mn/m | -$3.1Mn/m | -$2.5M |
| Investing Cash Flow | -$987Kn/m | -$2.2Mn/m | -$10.3M |
| Financing Cash Flow | $139K-96.3% | $3.7M-83.7% | $22.9M |
Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.
BRCNF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2210-K | FY2110-K | FY2010-K |
|---|---|---|---|
| Operating Margin | -4314.2% | -1776.7% | -11958.4% |
| Net Margin | -5982.6% | -238.7% | -14882.4% |
| Return on Equity | -36.3%-34.6pp | -1.7%+18.5pp | -20.2% |
| Return on Assets | -34.9%-33.3pp | -1.6%+13.2pp | -14.8% |
| Current Ratio | 7.30-2.8x | 10.09+0.2x | 9.91 |
| Liabilities-to-Equity | 0.040.0x | 0.04-0.3x | 0.36 |
| Asset Turnover | 0.010.0x | 0.010.0x | 0.00 |
| FCF Margin | -3478.7% | -1518.5% | -11158.8% |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| BURON NUTRASCIENCE CORP BRCNF | FY2022 | $137K | -$8.2M | N/A | $11.6M | — |
| STARCO BRANDS INC CL A STCB | FY2025 | N/A | -$20.9M | N/A | $20.4M | — |
| LIMITLESS X HOLDINGS INC LIMX | FY2025 | $947K | N/A | N/A | $4.6M | — |
Where BURON NUTRASCIENCE CORP Ranks
Frequently Asked Questions
What is BURON NUTRASCIENCE CORP's annual revenue?
BURON NUTRASCIENCE CORP (BRCNF) reported $137K in total revenue for fiscal year 2022. This represents a -33.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BURON NUTRASCIENCE CORP's revenue growing?
BURON NUTRASCIENCE CORP (BRCNF) revenue declined by 33.2% year-over-year, from $206K to $137K in fiscal year 2022.
Is BURON NUTRASCIENCE CORP profitable?
No, BURON NUTRASCIENCE CORP (BRCNF) reported a net loss of $8.2M in fiscal year 2022.
What is BURON NUTRASCIENCE CORP's EBITDA?
BURON NUTRASCIENCE CORP (BRCNF) had EBITDA of -$5.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.
What is BURON NUTRASCIENCE CORP's return on equity (ROE)?
BURON NUTRASCIENCE CORP (BRCNF) has a return on equity of -36.3% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.
What is BURON NUTRASCIENCE CORP's free cash flow?
BURON NUTRASCIENCE CORP (BRCNF) recorded an outflow of $4.8M in free cash flow during fiscal year 2022. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BURON NUTRASCIENCE CORP's operating cash flow?
BURON NUTRASCIENCE CORP (BRCNF) recorded an outflow of $4.7M in operating cash flow during fiscal year 2022, representing cash used by core business activities.
What are BURON NUTRASCIENCE CORP's total assets?
BURON NUTRASCIENCE CORP (BRCNF) had $23.5M in total assets as of fiscal year 2022, including both current and long-term assets.
What are BURON NUTRASCIENCE CORP's capital expenditures?
BURON NUTRASCIENCE CORP (BRCNF) invested $41K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.
How much does BURON NUTRASCIENCE CORP spend on research and development?
BURON NUTRASCIENCE CORP (BRCNF) invested $1.5M in research and development during fiscal year 2022.
What is BURON NUTRASCIENCE CORP's current ratio?
BURON NUTRASCIENCE CORP (BRCNF) had a current ratio of 7.30 as of fiscal year 2022, which is generally considered healthy.
What is BURON NUTRASCIENCE CORP's liabilities-to-equity ratio?
BURON NUTRASCIENCE CORP (BRCNF) had a liabilities-to-equity ratio of 0.04 as of fiscal year 2022, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2022, because the filing data we hold for that year carries no long-term debt figure.
What is BURON NUTRASCIENCE CORP's return on assets (ROA)?
BURON NUTRASCIENCE CORP (BRCNF) had a return on assets of -34.9% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.
What is BURON NUTRASCIENCE CORP's P/E ratio?
BURON NUTRASCIENCE CORP (BRCNF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2022). The market capitalization is $11.6M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BURON NUTRASCIENCE CORP's price-to-sales ratio?
BURON NUTRASCIENCE CORP (BRCNF) trades at 84.7x sales, its market capitalization divided by $137K revenue, FY2022. The market capitalization is $11.6M as of Oct 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is BURON NUTRASCIENCE CORP's Altman Z-Score?
BURON NUTRASCIENCE CORP (BRCNF) has an Altman Z-Score of 2.13, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BURON NUTRASCIENCE CORP's Piotroski F-Score?
BURON NUTRASCIENCE CORP (BRCNF) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BURON NUTRASCIENCE CORP's earnings high quality?
BURON NUTRASCIENCE CORP (BRCNF) reported a net loss of $8.2M while operations used $4.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BURON NUTRASCIENCE CORP cover its interest payments?
BURON NUTRASCIENCE CORP (BRCNF) reported an operating loss of $5.9M against $58K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.